Cost–effectiveness of sunitinib in metastatic renal cell carcinoma

References

• Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet373, 1119–1132 (2009).
   PubMed Web of Science ®Google Scholar
• Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat. Rev.34, 193–205 (2008).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N. Engl. J. Med.335, 865–875 (1996).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N. Engl. J. Med.356, 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol.24, 16–24 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA295, 2516–2524 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Michaelson MD, Rosenberg J et al. Sunitinib efficacy against advanced renal cell carcinoma. J. Urol.178, 1883–1887 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib versus interferon a in first-line treatment of patients with metastatic renal cell carcinoma. J. Clin. Oncol.27, 3584–3590 (2009).
   PubMed Web of Science ®Google Scholar
• Escudier B. Sunitinib for the management of advanced renal cell carcinoma. Expert Rev. Anticancer Ther.10(3), 305–317 (2010).
   PubMed Web of Science ®Google Scholar
• Escudier B, Kataja V. Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol.20(Suppl. 4), iv81–iv82 (2009).
   Web of Science ®Google Scholar
• Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo controlled Phase III trial. Lancet372, 449–456 (2008).
   PubMed Web of Science ®Google Scholar
• Norum J, Nieder C, Kondo M. Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations. J. Chemother.22(2), 75–82 (2010).
   PubMed Web of Science ®Google Scholar
• Négrier S, Remák E, Brown Rl, Kim ST, Charbonneau C, Motzer RJ. Economic evaluation of sunitinib vs. interferon-α (IFN-α) in first-line metastatic renal cell carcinoma (mRCC). Eur. J. Cancer5(Suppl. 4), 303 (2007).
   Google Scholar
• Thompson Coon J, Hoyle M, Green C et al. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol. Assess.14(2), 1–184 (2010).
   PubMed Web of Science ®Google Scholar
• Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics13(4), 397–409 (1998).
   PubMed Web of Science ®Google Scholar
• Ondrackova B, Demlova R. Sorafenib and sunitinib in metastatic renal cell carcinoma: cost-effectiveness analysis in reimbursement proceedings vs. data from clinical practice. Presented at : ISPOR 13th Annual European Congress. Prague, Czech Republic, 6–9 November 2010.
   Google Scholar
• Remák E, Charbonneau C, Négrier S, Kim ST, Motzer RJ. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J. Clin. Oncol.26(24), 3995–4000 (2008).
   PubMed Web of Science ®Google Scholar
• Chabot I, Rocchi A. How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma. Value Health13(6), 837–845 (2010).
   PubMed Web of Science ®Google Scholar
• Benedict A, Figlin RA, Sandström P et al. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. BJU Int. DOI: 10. 1111/j. 1464–410X. 2010. 09957 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Remák E, Brown R, Négrier S, Motzer RJ, Kim ST, Charbonneau C. Sunitinib vs. interferon-α (IFN-α) in first-line metastatic renal cell carcinoma (mRCC): An economic evaluation. Value Health10(6), A327–A328 (2007).
   Google Scholar
• Remák E, Mullins CD, Akobundu E, Charbonneau C, Woodruff K. Economic evaluations of sunitinib versus interferon-α (IFN-α) in first-line metastatic renal cell carcinoma (mRCC). J. Clin. Oncol.25(Suppl. 18S) (2007) (Abstract 6607).
   Google Scholar
• Topibulpong N, Tanasanvimon S, Parinyanitikul N, Vinayanuwattikun C, Sriuranpong V. economic implications of the first line treatment of advanced renal cell carcinoma in Thailand: a cost-effectiveness analysis. Presentedt at: ISPOR 4th Asia-Pacific Conference. Phuket, Thailand, 5–7 September 2010.
   Google Scholar
• Benedict A, Figlin RA, Charbonneau C, Kreif N, Hariharan S, Négrier S. Economic evaluation of sunitinib versus other new targeted therapies as first-line treatment of metastatic renal cell carcinoma (mRCC) in the United States. J. Clin. Oncol.27 (2009) (Abstract 17556).
   Google Scholar
• Remák E, Vioix H, Sandin R, Harmenberg U, Ullen A, Sandstom P. Cost effectiveness analysis of sunitinib, bevacizumab plus interferon-α and temsirolimus as first-line therapy of metastatic renal cell carcinoma in Sweden. Value Health12(7), A270 (2009).
   Google Scholar
• Silverio NM, Yang S, Alemao E. Cost-effectiveness analysis of temsirolimus vs. sunitinib malate in poor prognosis metastatic renal cell carcinoma (mRCC) in Portugal. Value Health12(7), A271 (2009).
   Google Scholar
• Paz-Ares L, del Muro JG, Grande E, Díaz S. Cost–effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System. J. Clin. Pharm. Ther.35(4), 429–438 (2010).
   PubMed Web of Science ®Google Scholar
• Purmonen T, Martikainen JA, Soini EJ, Kataja V, Vuorinen RL, Kellokumpu-Lehtinen PL. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland. Clin. Ther.30(2), 382–392 (2008).
   PubMed Web of Science ®Google Scholar
• Garduño-Espinosa J, Contreras-Hernandez I, Mould-Quevedo J, Salinas-Escudero G, Tapia-Valencia J, Davila-Loaiza G. A cost-utility analysis model for the second line treatment of metastatic renal cell carcinoma in Mexico. Value Health10(3), A132–A133 (2007).
   Google Scholar
• Purmonen T, Martikainen JA, Soini EJ, Kataja V, Kellokumpu-Lehtinen PL. Sunitinib malate provides additional survival and value for money as a second line treatment for metastatic renal cell carcinoma (mRCC) – an economic evaluation using Bayesian approach. Value Health10(6), A337 (2007).
   Google Scholar
• van Nooten F, Dewilde S, Van Belle S, Marbaix S. Cost-effectiveness of sunitinib as second line treatment in patients with metastatic renal cancer in Belgium. Value Health10(6), A329 (2007).
   Google Scholar
• Shih YC, Chien CR, Xu Y, Pan IW, Smith GL, Buchholz TA. Economic burden of renal cell carcinoma: part I – an updated review. Pharmacoeconomics29(4), 315–329 (2011).
   PubMed Web of Science ®Google Scholar
• Systematic Reviews. CRD’s guidance for undertaking reviews in health care. Centre for Reviews and Dissemination. University of York, York, UK (2009).
   Google Scholar
• Cochrane Handbook for Systematic Reviews of Interventions. Version 5. 1. 0. Higgins JPT, Green S (Eds). The Cochrane Collaboration (2011).
   Google Scholar
• Purmonen T, Nuttunen P, Vuorinen R, Pyrhönen S, Kataja V, Kellokumpu-Lehtinen P. Current and predicted cost of metastatic renal cell carcinoma in Finland. Acta. Oncol.49(6), 837–843 (2010).
   PubMed Web of Science ®Google Scholar
• Cella D, Michaelson MD, Bushmakin AG et al. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-α in a Phase III trial: final results and geographical analysis. Br. J. Cancer102(4), 658–664 (2010).
   PubMed Web of Science ®Google Scholar
• Mickisch G, Gore M, Escudier B, Procopio G, Walzer S, Nuijten M. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib. Br. J. Cancer102(1), 80–86 (2010)
   PubMed Web of Science ®Google Scholar
• Mickisch GH, Schwander B, Escudier B et al. Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. Clinicoecon. Outcomes Res.3, 19–27 (2011).
   PubMedGoogle Scholar
• Mills EJ, Rachlis B, O’Regan C, Thabane L, Perri D. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. BMC Cancer9(34) (2009).
   PubMedGoogle Scholar
• Benedict A, Charbonneau C, Hidi J, Kim ST, Négrier S. Economic evaluation of sunitinib, sorafenib, bevacizumab/interferon-α or temsirolimus in 1st-line treatment of metastatic renal cell carcinoma (mRCC): an indirect comparison. J. Clin. Oncol.26, (2008) (Abstract 5048).
   Google Scholar
• Benedict A, Charbonneau C, Kim ST, Négrier S. Cost-effectiveness of sunitinib (SU), sorafenib (SFN), temsirolimus (TMS), and bevacizumab plus interferon-α (BEV/IFN) as 1st-line therapy for metastatic renal cell carcinoma (mRCC) – an indirect comparison. Ann. Oncol.19(Suppl. 8), 227 (2008).
   Google Scholar
• Sandin R, Munir U, Benedict A et al. economic evaluation of sunitinib first-line for metastatic renal cell carcinoma versus sorafenib, temsirolimus and bevacizumab plus interferon-α in the Swedish health service setting. Value Health11(6), A468 (2008).
   Google Scholar
• Munir U, Benedict A, Borgman B et al. Cost-effectiveness of sunitinib (SU) vs sorafenib (SFN), temsirolimus (TMS) and bevacizumab plus interferon-α (BEV/IFN) as first-line therapy for metastatic renal cell carcinoma (mRCC) - adaptation for the Swedish health service. Ann. Oncol.19(Suppl. 8), 228 (2008).
   Google Scholar
• Calvo E, Maroto-Rey P, Gonzalez-Larriba JL et al. Cost-effectiveness (CE) evaluation of sunitinib as first-line treatment for metastatic renal cell carcinoma (mRCC) in Spain. Abstract 409. Presented at: ASCO Genitourinary Cancers Symposium. San Francisco, CA, USA, 5–7 March 2010.
   Google Scholar
• Diaz S, Calvo E, Maroto P, Puente J, Lopez-Brea M, Castellano D. Cost-effectiveness and cost-utility analysis of sunitinib (SU) vs sorafenib (SFN) and bevacizumab plus interferon-α (BEV/IFN) as first-line treatment for metastatic renal cell carcinoma (mRCC) in Spain. Ann. Oncol.19(Suppl. 8), 227 (2008).
   Google Scholar
• Godoy JI, Cardona AF, Cáceres H et al. Cost-effectiveness analysis of first-line treatment for metastatic renal cell carcinoma in Colombia (ONCOLGroup study). Presented at: ISPOR 2 Latin America Conference, Rio de Janeiro, Brazil, 10–12 September 2009.
   Google Scholar
• Godoy JI, Cardona AF, Cáceres H et al. Cost-effectiveness analysis of first-line treatment for metastatic renal cell carcinoma (mRCC) in Colombia (ONCOLGroup study). J. Clin. Oncol.27(Suppl. 15) (2009) (Abstract 16150).
   Google Scholar
• Cáceres H, Godoy JI, Cardona AF et al. Economic evaluation of sunitinib vs. interferon-α (IFN-α) in first-line treatment of metastatic renal cell carcinoma (mRCC) in Colombia. Value Health11(3), A100 (2008).
   Google Scholar
• Salinas-Escudero G, Contreras-Hernandez I, Mould-Quevedo J. Cost-effectiveness and cost-utility analysis of sunitinib vs sorafenib and bevacizumab plus interferon-α as first-line treatment for metastatic renal cell carcinoma in Mexico. Value Health12(7), A497 (2009).
   Google Scholar
• Mould-Quevedo J, Tenorio C, Vargas J et al. Pharmacoeconomic evaluation of sunitinib malate for first-line treatment of metastatic renal cell carcinoma in Mexico. Presented at: ISPOR 14th Annual International Meeting. Orlando, FL, USA, 18 May 2009.
   Google Scholar
• Greenberg D. Economic evaluation of sunitinib, sorafenib, bevacizumab/interferon α and temsirolimus in first line treatment of metastatic renal cell carcinoma in Israel. Value Health12(3), A42 (2009).
   Google Scholar
• Teich V, Hashizume CM, Marinho T, Charbonneau C, Naves A. Economic evaluation of sunitinib vs. interferon-α and bevacizumab plus interferon-α in the treatment of metastatic renal cell carcinoma (ccrm) – Brazilian private health system perspective. Value Health13(3), A37 (2010).
   Google Scholar
• Aiello EC, Muszbek N, Richardet E, Lingua A, Charbonneau C, Remák E. Cost-effectiveness of new targeted therapy sunitinib malate as second line treatment in metastatic renal cell carcinoma in Argentina. Value Health10(3), A127–A128 (2007).
   Google Scholar